References 1 Whipple GH. A hitherto undescribed disease characterized anatomically by deposits of fat and fatty acids in the intestinal and mesenteric lymphatic tissues.
Sir, Antiretroviral (ARV) regimens to treat MDR HIV strains often require the use of a ritonavir-boosted PI, usually darunavir, in combination with other drugs. 1 Aspergillosis is a serious infection in immunocompromised patients and the drug of choice for its treatment is voriconazole 2 but it shows a complex drug-drug interaction profile. Ritonavir induces the CYP2C19 isoenzyme, leading frequently to insufficient drug levels of voriconazole, 3 contraindicating its co-administration. 4 -7 Consequently, in patients with MDR HIV infections and aspergillosis, therapeutic options are limited. Cobicistat shows a theoretically better drug-drug interaction profile, due to the more selective 3A4 isoenzyme inhibition, but clinical experience with drugs other than ARVs is lacking. 3, 8 A middle-aged male patient with HIV since 1987, treated since the early 1990s with several ARV regimens and experienced multiple virological failures causing an MDR strain (62V/65R/ 101E/181C/184I mutations, conferring resistance to lamivudine/ emtricitabine/didanosine/abacavir/nevirapine/efavirenz/rilpivirine/ etravirine and partial resistance to tenofovir). In 2014 he had an undetectable viral load and CD4 lymphocyte count .1000 cells/mm 3 , and was on 800/100 mg of darunavir/ritonavir once daily and 400 mg of raltegravir twice daily. He never developed an AIDS-related opportunistic infection. He also had a severe chronic obstructive pulmonary disease. In July 2014, he was admitted for a respiratory infection and treated with broad-spectrum antibiotics and high doses of systemic steroids with incomplete response. Then invasive pulmonary aspergillosis was diagnosed ( Figure 1 ). The chosen antifungal drug was liposomal amphotericin B plus anidulafungin. However, the patient showed no clinical response, so the antifungal regimen was modified to 200 mg of voriconazole twice daily and the ARV regimen was changed to enfuvirtide, zidovudine, tenofovir and raltegravir at the usual doses. On this treatment, he clinically improved and was discharged. After 4 months the patient requested an ARV regimen change, due to intolerance to enfuvirtide injections. The regimen chosen then was 150/150/200/300 mg of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (co-formulated as Stribild w ) once daily and 800 mg of darunavir once daily.
To check the pharmacokinetics of this drug combination, a complete 24 h pharmacokinetic curve was performed for 800 mg of darunavir once daily and 200 mg of voriconazole twice daily on this regimen, showing a darunavir C min of 0.2 mg/mL, C max of 5.9 mg/mL at 4 h and an AUC of 51.2 mg . h/L. For voriconazole, the C min was 0.31 mg/mL, the C max was 1.92 mg/mL at 2 h post-administration and the AUC was 11.9 mg . h/L. These values represented a slight decrease in AUC for voriconazole ( 20%) and for darunavir ( 15%), compared with reference values. Voriconazole plasma concentrations were measured by validated reverse-phase HPLC adapted to a UV/Vis detector. The limit of quantification was 0.10 mg/mL. Elvitegravir plasma levels were not available. The results of these pharmacokinetic curves were only available later on during the clinical course and thus were not used for dose adjustments or therapeutic decisions. Voriconazole doses were adapted in real time according to C min monitoring and were progressively increased to 400 mg twice daily to reach the target plasma level of 1 mg/mL. 9 The patient presented good tolerance and complete clinical resolution after 9 months. Plasma HIV viral load remained consistently undetectable.
Voriconazole is metabolized by the hepatic P450 cytochrome isoenzymes CYP2C19 and, to a minor extent, CYP2C9 and CYP3A4. 6 Its therapeutic window is narrow, with a high risk of side effects when serum levels are 3 -5 times higher than the minimal threshold for efficacy. 2 It shows a well-described drugdrug interaction profile with several ARV drugs, particularly those metabolized by the P450 cytochrome. Ritonavir is mainly a CYP3A4 isoenzyme inhibitor, but also a CYP2C19 and CYP2C9 inducer, so it decreases voriconazole levels. Then, in patients with MDR HIV infections treated with a PI and presenting with aspergillosis, therapeutic options are limited due to the contraindicated use of concomitant voriconazole and ritonavir-boosted PIs. Nevertheless, cobicistat could be an alternative in those cases, due to its higher specificity for 3A4 inhibition. 8, 10 However, clinical experience is extremely limited beyond cobicistat co-administration with elvitegravir and some PIs. Despite that the combination of elvitegravir/cobicistat and darunavir is not recommended for the potential reduction of darunavir plasma levels (as seen in our case), this reduction of darunavir AUC has, probably, no clinical relevance for simplification of patients virologically suppressed for long periods.
In conclusion, our case is original for several reasons. First, as far as we know, this is the first report of co-administration of cobicistat, darunavir and voriconazole (in the context of a complex ARV regimen). Second, it offers clinical insight into the efficacy of this antimicrobial regimen in a real-life setting, the maintenance of undetectable viral load and a complete clinical response to pulmonary aspergillosis. Finally, it provides evidence of the potential usefulness of this ARV combination for simplification in experienced patients, a two-pill regimen combination that could be active in patients with extensive ARV drug resistance, although more clinical experience is needed. 
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